newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

biotech / news / / Reuters

Several drugmakers have been developing lower-cost versions of Novo Nordisk's diabetes drug Ozempic.

India was the first major market to launch copycat semaglutide after patent expiries in March.

KEY POINTS
COMPANIES
Read the full story on Reuters →
Share X LinkedIn

Summarized by Newsio from Reuters. How we summarize →